Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience

BACKGROUND: Most biologic therapies for psoriasis are delivered via subcutaneous injection. Ixekizumab, an anti-interleukin 17A monoclonal antibody approved for patients with moderate-to-severe plaque psoriasis, is delivered subcutaneously via prefilled syringe or autoinjector. Here we report the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Callis Duffin, Kristina, Bukhalo, Michael, Bobonich, Margaret A, Shrom, David, Zhao, Fangyi, Kershner, James R, Gill, Anne, Pangallo, Beth, Shuler, Catherine L, Bagel, Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067052/
https://www.ncbi.nlm.nih.gov/pubmed/27785115
http://dx.doi.org/10.2147/MDER.S113752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067052/
https://www.ncbi.nlm.nih.gov/pubmed/27785115
http://dx.doi.org/10.2147/MDER.S113752

Ejemplares similares